middle.news
Patrys Secures Key Partners for RLS-2202 Phase 1A Trial Targeting Q3 2026 Start
9:31am on Wednesday 20th of May, 2026 AEST
•
Healthcare
Read Story
Patrys Secures Key Partners for RLS-2202 Phase 1A Trial Targeting Q3 2026 Start
9:31am on Wednesday 20th of May, 2026 AEST
Key Points
CMAX selected as Phase 1A clinical trial site
Alithia Life Sciences appointed as CRO
Trial initiation planned for Q3 2026
RLS-2202 targets delirium treatment in acute care
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE